NCT00709059View on ClinicalTrials.gov

Efficacy of PegIntron and Rebetol in Previously Untreated Patients With Chronic Hepatitis C Infected With HCV Genotype 1/4/5/6 (Study P04243)

CompletedOBSERVATIONAL
Enrollment

538

Participants

Timeline

Start Date

December 31, 2004

Primary Completion Date

December 31, 2009

Study Completion Date

December 31, 2009

Conditions
Hepatitis C, Chronic
Interventions
BIOLOGICAL

PegIntron (peginterferon alfa-2b; SCH 54031)

PegIntron 1.5 ug/kg body weight per week subcutaneously for 48 weeks

DRUG

Rebetol (ribavirin; SCH 18908)

Rebetol administered based on body weight 800-1200 mg/day (\<65 kg: 800 mg; 65 - 85 kg: 1000 mg; \>85 kg: 1200 mg) orally for 48 weeks

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00709059 - Efficacy of PegIntron and Rebetol in Previously Untreated Patients With Chronic Hepatitis C Infected With HCV Genotype 1/4/5/6 (Study P04243) | Biotech Hunter | Biotech Hunter